BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//European Brain Council (EBC) - ECPv6.15.19//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:European Brain Council (EBC)
X-ORIGINAL-URL:https://www.braincouncil.eu
X-WR-CALDESC:Events for European Brain Council (EBC)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20221206T140000
DTEND;TZID=UTC:20221206T160000
DTSTAMP:20260414T143409
CREATED:20221025T180039Z
LAST-MODIFIED:20230102T141247Z
UID:41602-1670335200-1670342400@www.braincouncil.eu
SUMMARY:Psychedelic-assisted therapies in the treatment of brain disorders
DESCRIPTION:The Psychedelic Access and Research European Alliance and European Brain Council were pleased to hold the event\, “Psychedelic-assisted therapies in the treatment of brain disorders”\, hosted by MEPs Jarosław Duda (EPP\, PL) and Alex Agius Saliba (S&D\, MT) in the European Parliament on 6 December 2022 at 14:00 –16:00 CET. \nUnderstanding our brain is an enormous task and brain research is extremely complex. Despite huge scientific efforts\, mental\, neurological and substance use disorders are leading the list of diseases without a known cure. Estimates show that – at the current pace – by 2040 e can prevent only a small proportion of a burden from neurological and mental health conditions: 23% and 14% respectively. \nHowever\, innovations that completely change the lives of patients continue to emerge and psychedelic-assisted therapies are one such area. Rapidly growing\, rigorous\, and compelling body of research demonstrates that these therapies can be a potent new class of treatments for mental\, neurological and substance use disorders. \nIn 2021 alone – ground-breaking findings were published in prestigious journals such as Lancet\, Nature Medicine\, and New England Journal of Medicine. For example\, a phase 3 clinical trial demonstrated that 67% of participants who received the MDMA-assisted therapy no longer had PTSD after two months of therapy. A double-blinded randomized study published in August 2022 in JAMA Psychiatry found that – with 2 doses of psilocybin paired with psychotherapy – nearly half of participants had stopped drinking entirely by the end of the 8-month trial. Psychedelics are also increasingly being researched in the context of neurological disorders such as headaches. \nWhile no treatment is without risks\, research shows that psychedelic-assisted therapy is generally physiologically and psychologically safe when delivered in controlled and supportive settings and psychedelic compounds are non-toxic and non-habit forming. \nThe President Biden Administration’s letter from May 2022 anticipates that US regulators will approve MDMA and psilocybin within the next two years for treatments of PTSD and depression. The administration is “exploring the prospect of establishing a Federal Task Force to monitor and address the numerous complex issues associated with these substances”. In the next few years\, millions of Europeans may be eligible for a prescription of psychedelic therapies and we need to start preparing for this now. \nAgendaLook back at the event
URL:https://www.braincouncil.eu/event/psychedelic-assisted-therapies-in-the-treatment-of-brain-disorders/
LOCATION:European Parliament\, Rue Wiertz 60\, Brussels\, 1047\, Belgium
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20221207T160000
DTEND;TZID=UTC:20221207T173000
DTSTAMP:20260414T143409
CREATED:20221201T123233Z
LAST-MODIFIED:20230102T134701Z
UID:42963-1670428800-1670434200@www.braincouncil.eu
SUMMARY:Rare Neurological Diseases in the EU: The Importance of Early Diagnosis and Real World Evidence to Drive Better Patient Outcomes
DESCRIPTION:On 7 December 2022 at 16:00-17:30\, the European Alliance for Patient Access (EAfPA)\, with support of the European Brain Council (EBC) and European Federation of Neurological Associations (EFNA)\, hosted an event in the European Parliament on Rare Neurological Diseases in the EU\, exploring the importance of early diagnosis and real-world evidence (RWE) to drive better patient outcomes. \nHosted by MEP Tilly Metz (Greens/EFA\, Luxembourg)\, European stakeholders convened to discuss the critical need for improved access to care\, services\, and treatment for patients living with rare neurological diseases. Conversations were centred on revisions of current legislation to meet the needs of patients living with a rare neurological condition\, as well as the importance of RWE and early diagnosis. \nFrédéric Destrebecq\, EBC Executive Director\, presented the Value of Treatment for rare neurological and neurometabolic diseases case study results and 2022 call to action. \nRead moreRegistration is now closed. The draft agenda is included below: \nDraft Agenda - Rare Neurological Diseases in the EU- The Importance of Early Diagnosis and Real World Evidence to Drive Better Patient Outcomes
URL:https://www.braincouncil.eu/event/42963/
LOCATION:European Parliament\, Rue Wiertz 60\, Brussels\, 1047\, Belgium
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20221208T140000
DTEND;TZID=UTC:20221208T160000
DTSTAMP:20260414T143409
CREATED:20221121T115227Z
LAST-MODIFIED:20230103T101246Z
UID:42621-1670508000-1670515200@www.braincouncil.eu
SUMMARY:‘The Future of Brain Health: Clinically Informed & Patient-Centred Brain Research’
DESCRIPTION:EBC Member\, the European Academy of Neurology\, hosted an event on ‘The Future of Brain Health: Clinically Informed & Patient-Centred Brain Research’ on 8 December in the European Parliament. Held under the auspices of the Czech Presidency of the Council of the European Union and hosted by MEP Ondřej Knotek\, the event highlighted the importance and need for research\, as well as the main priorities and gaps within neurology\, which if addressed will have major impact on brain health. \nThe event took place in-person at the European Parliament in Brussels on December 8 from 14:00 to 16:00 CET. \nEBC President\, Prof. Wolfgang Oertel\, took part in the panel discussion “The Future of Brain Research in Europe: Key Priorities and How They Can Be Addressed”\, together with Orla Galvin (European Federation of Neurological Associations)\, Paweł Świeboda (EBRAINS) and Frances-Catherine Quevenco (Women’s Brain Project). The panel was moderated by Jacqui Thornton. \nLook back at the event and watch the full recording and the highlights video below. \nFull Recording of the Future of Brain Health EventHighlights video
URL:https://www.braincouncil.eu/event/the-future-of-brain-health-clinically-informed-patient-centred-brain-research/
LOCATION:European Parliament\, Rue Wiertz 60\, Brussels\, 1047\, Belgium
END:VEVENT
END:VCALENDAR